{"id":458135,"date":"2019-12-19T16:34:01","date_gmt":"2019-12-19T16:34:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=458135"},"modified":"2019-12-19T16:34:01","modified_gmt":"2019-12-19T16:34:01","slug":"fannin-innovation-studio-attracts-experienced-financiermd-to-houston","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/fannin-innovation-studio-attracts-experienced-financiermd-to-houston_458135.html","title":{"rendered":"Fannin Innovation Studio Attracts Experienced Financier\/MD to Houston"},"content":{"rendered":"
\"Fannin<\/a><\/div>\n

Houston, TX (December 2019) – <\/strong>Praveen Kudithipudi, MBBS, MBA, joined Fannin Innovation Studio as Director of Business Development. He received his medical degree from Manipal University, India before specializing in neuroscience in the United Kingdom and receiving his MBA from New York University. Prior to joining Fannin, Dr. Kudithipudi worked in New York, with over 15 years of experience in banking, venture capital, investments and building new companies.<\/p>\n

At Fannin Innovation Studio, Dr. Kudithipudi supports licensing of portfolio technologies, including therapeutics and devices, and helps establish collaborations with pharmaceutical companies and academic institutions.<\/p>\n

“I am excited to have a wonderful opportunity to work at Fannin,” said Dr. Kudithipudi. “Fannin builds successful life sciences startups while helping to catalyze the formation of a thriving and sustainable life sciences entrepreneurship ecosystem in Houston. The opportunity to lead licensing, diligence, and collaboration efforts with academic institutions and biotechnology companies here in Houston is truly a unique opportunity.”<\/p>\n

\n

“We are excited to have someone with the range of experiences and caliber of Praveen on the team.  In our business, we look for high potential technologies at an early stage”, said Dr. Atul Varadhachary, Fannin Managing Partner. “Having someone with both a medical background and Wall Street know-how is invaluable to us as we review opportunities and reach out to prospective development partners. In addition, I’m excited that Praveen will be leading some of our professional development workshops for the scientists and engineers at Fannin on the financial aspects of entrepreneurship to build their business acumen.”<\/p>\n<\/div>\n

About Fannin Innovation Studio<\/strong><\/p>\n

Houston-based Fannin Innovation Studio is an early-stage life sciences development group focused exclusively on commercializing biotech and medtech technologies. Fannin partners with life science innovators to create startup companies, providing management, funding, and business development. To further bridge the commercialization gap, Fannin’s fellowship and internship programs provide aspiring entrepreneurs with hands-on development experience with its portfolio companies. For more information, visit <\/em>www.FanninInnovation.com<\/em><\/a>, come by the Studio at 3900 Essex Lane — Suite 575 in Houston, or email us at <\/em>innovate@fannininnovation.com<\/em><\/a>.<\/em><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Fannin Innovation Studio<\/a>
Contact Person:<\/strong> Serena Miggins
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 713-966-5844
City:<\/strong> Houston
State:<\/strong> Texas
Country:<\/strong> United States
Website:<\/strong> www.FanninInnovation.com<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Houston, TX (December 2019) – Praveen Kudithipudi, MBBS, MBA, joined Fannin Innovation Studio as Director of Business Development. He received his medical degree from Manipal University, India before specializing in neuroscience in the United Kingdom and receiving his MBA from … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,406,420,411,404],"tags":[],"class_list":["post-458135","post","type-post","status-publish","format-standard","hentry","category-Business","category-Pharmaceuticals-Biotech","category-Science","category-Technology","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/458135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=458135"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/458135\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=458135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=458135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=458135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}